AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22801963
Drug: FA (fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA (fludarabine and cytarabine) and FLAG (fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor)
Trial: 22805291
Drug: Trametinib 2
RxNorm normalized name: trametinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib 2 mg once daily (recommended phase 2 dose)
Trial: 22805291
Drug: Trametinib 3
RxNorm normalized name: Tramétinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib 3 mg once daily (maximum tolerated dose)
Trial: 22805292
Drug: Trametinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (oral MEK inhibitor)
Trial: 22812667
Drug: Unilateral subretinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral subretinal injection in a clinical gene therapy trial
Trial: 22813439
Drug: Proton-pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-pump inhibitor (PPI) test with esomeprazole (40 mg once daily for 2 weeks)
Trial: 22815703
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m² and irinotecan 75 mg/m² weekly times four on a six week cycle (Cohort I)
Trial: 22815703
Drug: Gemcitabine 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 750 mg/m² and irinotecan 75 mg/m² weekly times three on a four week cycle (Cohort II)
Trial: 22816487
Drug: Decitabine 20
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 20 mg/m(2) daily for 5 days every 4 weeks
Trial: 22816487
Drug: Decitabine 20
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 20 mg/m(2)
Trial: 22817698
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 intravenously every 3 weeks for 6 cycles
Trial: 22819172
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg per day, orally
Trial: 22824929
Drug: Propofol 3-4
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 3-4 mg/kg/hr
Trial: 22824929
Drug: Propofol 3-4
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 3-4 mg/kg/hr (after isoflurane)
Trial: 22824936
Drug: Increasing cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing cumulative fluid balance (mL/kg) on day 3
Trial: 22824936
Drug: Daily fluid
RxNorm normalized name: ENSULIZOLE 4 g in 100 mL / OCTINOXATE 5 g in 100 mL / OCTOCRYLENE 10 g in 100 mL / TITANIUM DIOXIDE 5 g in 100 mL / OCTISALATE 5 g in 100 mL TOPICAL CREAM [EXEL CLARIFYING LINE DAILY FLUID SUN SHIELD WHITE COLOR BROAD SPECTRUM SPF 60 PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily fluid balance on days 1-3 and cumulative fluid balance on days 1-7
Trial: 22826359
Drug: Clopidogrel added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel added to aspirin
Trial: 22831708
Drug: Rosuvastatin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (2.5 mg once daily, up-titrated to a maximum of 20 mg/day)
Trial: 22833362
Drug: Rontalizumab (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rontalizumab (0.3 to 10 mg/kg, IV or subcutaneous)
Trial: 22833362
Drug: Rontalizumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rontalizumab (3 mg/kg and 10 mg/kg IV)
Trial: 22833546
Drug: Carfilzomib 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib 20 mg/m² intravenously twice weekly for 3 of 4 weeks in cycle 1, then 27 mg/m² for ≤ 12 cycles
Trial: 22835045
Drug: Cyclophosphamide 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 1500 mg/m(2), vincristine, rituximab, prednisone, methotrexate 3 g/m(2), and intrathecal cytarabine for 2 cycles, followed by high-dose cyclophosphamide (50 mg/kg/day for 4 days) and rituximab.
Trial: 22837004
Drug: Vorinostat (VOR);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (VOR); single dose administered to patients
Trial: 22837492
Drug: ALVAC-HIV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-HIV and AIDSVAX B/E vaccine
Trial: 22838970
Drug: Thiazolidinediones and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazolidinediones and oral combination drugs
Trial: 22839200
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus capecitabine (capecitabine 2000 mg/m² daily in two divided doses, days 1-14, every 21 days; lapatinib 1250 mg once daily)
Trial: 22839504
Drug: Intravenous endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous endotoxin (LPS) injection
Trial: 22840761
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (.5 mg/kg) administered open-label three times weekly over a 12-day period
Trial: 22842843
Drug: Soluble receptor
RxNorm normalized name: Soluble receptor fused to part of an antibody that is designed to block the growth factor activin a
DrugBank: STM-217 (DB17358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble receptor activator of nuclear factor-κB ligand in HIV-infected individuals
Trial: 22843211
Drug: AZD8055 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8055 10 mg
Trial: 22843211
Drug: AZD8055 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8055 40 mg
Trial: 22843211
Drug: AZD8055 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8055 60 mg
Trial: 22843211
Drug: AZD8055 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8055 90 mg
Trial: 22847303
Drug: Allogeneic stem
RxNorm normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic stem cell transplantation (SCT) with partial T cell depletion (TCD) and preemptive donor lymphocyte infusion (DLI).
Trial: 22847303
Drug: Donor lymphocyte
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor lymphocyte infusion (DLI) for residual disease.
Trial: 22848378
Drug: AS03-adjuvanted pandemic
RxNorm normalized name: pangamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted pandemic vaccine (Pandemrix®)
Trial: 22848772
Drug: rBS-WC oral
RxNorm normalized name: cholera, WC-rBS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rBS-WC oral cholera vaccine (at least one dose)
Trial: 22850119
Drug: HPV-16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 vaccine trial control group
Trial: 22854002
Drug: Enzyme-assisted subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-assisted subcutaneous infusion (EASI) using human recombinant hyaluronidase (HRH)
Trial: 22854293
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of non-prescribed medications
Trial: 22854661
Drug: 3.75 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 µg HA AS03-adjuvanted H1N1 2009 vaccine
Trial: 22855388
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MCV4) in the prior-MPSV4 group (n = 153)
Trial: 22855388
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MCV4) in the meningococcal vaccine-naïve group (n = 85)
Trial: 22855388
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of MCV4 in both groups
Trial: 22856551
Drug: Intensified LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified LDL-C lowering therapy (various regimens including simvastatin/ezetimibe fixed-dose combination, add-on ezetimibe, and statin therapy at maintained or increased doses)
Trial: 22856636
Drug: C1 esterase
RxNorm normalized name: C1 esterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1 esterase inhibitor (C1-INH) concentrate at a dosage of 20 U/kg
Trial: 22856636
Drug: C1 esterase
RxNorm normalized name: C1 esterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1 esterase inhibitor (C1-INH) concentrate
Trial: 22859235
Drug: CP-690,050 (tasocitinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,050 (tasocitinib) at doses greater than 5 mg
Trial: 22859235
Drug: CP-690,050 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,050 at 2, 5, and 15 mg twice daily
Trial: 22868877
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment with amisulpride for 6 weeks
Trial: 22868877
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment with amisulpride
Trial: 22871230
Drug: Computer metabolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer metabolic system model for insulin infusion rates; short-term trials (24 hours) on 8 infants.
Trial: 22871230
Drug: Computer metabolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer metabolic system model for insulin infusion rates; long-term trials on 22 infants.
Trial: 22871230
Drug: Insulin infusions
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin infusions determined by sliding scales and clinician intuition; retrospective cohort of 21 patients.
Trial: 22875626
Drug: Deferasirox (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (30 mg/kg/day)
Trial: 22875626
Drug: Deferoxamine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferoxamine (40 mg/kg/day)
Trial: 22875626
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of deferasirox and deferoxamine
Trial: 22875883
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of ultrasmall superparamagnetic particles of iron oxide (4 mg/kg)
Trial: 22877866
Drug: GCSF-mobilized CD34+
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCSF-mobilized CD34+ cell therapy
Trial: 22878519
Drug: BMS-690514 100
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-690514 100 mg
Trial: 22878519
Drug: BMS-690514 200
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-690514 200 mg
Trial: 22878551
Drug: Hypocaloric, isonitrogenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric, isonitrogenous nutrition administered via intravenous infusion of glucose with amino acids over 72 hours (24 hours before to 48 hours after surgery). Glucose provided 50% and amino acids provided 20% of the patient's measured resting energy expenditure.
Trial: 22880942
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (0.3 mg/kg for <6 years, 20 mg or 40 mg tablets for ≥6 years)
Trial: 22885330
Drug: TMC435 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 (200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNα-2a and RBV) for 4 weeks, followed by PegIFNα-2a and RBV until week 48
Trial: 22885330
Drug: TMC435 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 (200 mg once daily) as monotherapy for 5 days
Trial: 22889943
Drug: Compliance with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliance with anemia targets (Hb 11.0-12.0 g/dl, transferrin saturation ratio ≥20%, ferritin 100-500 ng/ml)
Trial: 22892888
Drug: SENSIMED Triggerfish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SENSIMED Triggerfish CLS; Sensimed AG, for patients not on glaucoma medication.
Trial: 22892888
Drug: SENSIMED Triggerfish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SENSIMED Triggerfish CLS; Sensimed AG, for patients on glaucoma medication.
Trial: 22892920
Drug: Captopril, 25
RxNorm normalized name: Captopril, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril, 25 mg, administered orally
Trial: 22894607
Drug: Gemcitabine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine treatment in mice bearing PDAC xenografts
Trial: 22894827
Drug: etanercept treatment
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: etanercept treatment (25 mg biweekly for 2 weeks)
Trial: 22895887
Drug: 16 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy
Trial: 22896000
Drug: Subcutaneous omacetaxine
RxNorm normalized name: OMACETAXINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous omacetaxine 1.25 mg/m² twice daily, days 1-14, every 28 days until hematologic response or a maximum of 6 cycles, then days 1-7 every 28 days as maintenance
Trial: 22896000
Drug: Subcutaneous omacetaxine
RxNorm normalized name: OMACETAXINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous omacetaxine 1.25 mg/m²
Trial: 22897944
Drug: sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sunitinib 50 mg/day (4 weeks on treatment, 2 weeks off treatment)
Trial: 22899582
Drug: Oral lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral lenalidomide 25 mg Days 1-21 with a 7-day break after each cycle
Trial: 22901459
Drug: Canakinumab, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab, 150 mg subcutaneously every 8 weeks for 6 months
Trial: 22901847
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a) treatment with SC injections of leuprolide acetate (LA; Procren 3.75 mg every 28th day)
Trial: 22901847
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a) treatment
Trial: 22902483
Drug: Chemotherapy during
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy during pregnancy (median of four cycles, range one to eight); 197 women received chemotherapy, including 178 with anthracycline, 15 with cyclophosphamide, methotrexate, and fluorouracil, and 14 with taxane.
Trial: 22902483
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in utero
Trial: 22902483
Drug: Starting chemotherapy
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting chemotherapy during pregnancy
Trial: 22904181
Drug: 18F-FDG PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-FDG PET/CT with 250-μg cosyntropin injection
Trial: 22904181
Drug: Ovarian venous
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian venous sampling after cosyntropin administration
Trial: 22906363
Drug: Initial tidal
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial tidal volume (VT) < 8 mL/kg predicted body weight (PBW)
Trial: 22906363
Drug: Initial tidal
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial tidal volume (VT) ≥ 8 mL/kg predicted body weight (PBW)
Trial: 22906363
Drug: Initial tidal
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial tidal volume (VT) ≥ 8 mL/kg PBW
Trial: 22909164
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human C1 inhibitor (rhC1-INH) 2100 U
Trial: 22909342
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 (2 MIU/day for 14 days)
Trial: 22909342
Drug: Adoptive cell
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive cell therapy with TIL infusion
Trial: 22909342
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of adoptive cell therapy and low-dose IL-2
Trial: 22910104
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of apremilast orally twice daily for 12 weeks
Trial: 22911183
Drug: Deferasirox 250
RxNorm normalized name: deferasirox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox 250 mg/d, increased to 500 mg/d after 2 months if new blisters continued to develop
Trial: 22911730
Drug: Bezafibrate (BF)
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (BF) at a dose of 400 mg daily for 12 weeks, followed by 800 mg daily for another 12 weeks.
Trial: 22913907
Drug: Cyclosporine (100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (100-mg capsule)
Trial: 22915450
Drug: Vorinostat (SAHA);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (SAHA); individualized dose escalation; specific dosage and duration not provided.
Trial: 22915641
Drug: Lenalidomide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (10 mg/d for 21 days; 28-day cycle) and Azacitidine (75 mg/m(2)/d for 5 days)
Trial: 22915641
Drug: Lenalidomide and
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide and Azacitidine combination
Trial: 22915649
Drug: Rozrolimupab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rozrolimupab (75 to 300 μg/kg)
Trial: 22915649
Drug: Rozrolimupab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rozrolimupab (300 μg/kg)
Trial: 22920644
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of novel agents with high cut-off hemodialysis membrane
Trial: 22920644
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for MCN (urgent symptomatic measures and chemotherapy)
Trial: 22922531
Drug: Aflibercept 4
RxNorm normalized name: aflibercept 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 4 mg/kg IV q14 days (28-day cycles) until disease progression or prohibitive toxicity
Trial: 22925036
Drug: Fondaparinux 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 1.5 mg qd for 6 to 15 days
Trial: 22925178
Drug: Heparin-grafted membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-grafted membrane with ordinary heparin dose
Trial: 22927100
Drug: Scoring balloon
RxNorm normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scoring balloon for side branch and drug-eluting stent for main vessel
Trial: 22927248
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cell (MSC) treatment
Trial: 22929184
Drug: Idursulfase weekly
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idursulfase weekly group
Trial: 22929184
Drug: Idursulfase treatment
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idursulfase treatment group (extension phase)
Trial: 22930806
Drug: Ciprofloxacin (oral)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (oral) for 14 days
Trial: 22935486
Drug: Peginesatide administered
RxNorm normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginesatide administered intravenously every 4 weeks for up to 6 doses.
Trial: 22935486
Drug: Cohorts using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts using tiered dose conversion tables.
Trial: 22935486
Drug: Cohorts using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts using an erythropoiesis-stimulating agent-free interval.
Trial: 22935620
Drug: 400-μg sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400-μg sublingual misoprostol as first-line treatment
Trial: 22936711
Drug: Riociguat (1.0-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (1.0-2.5 mg three times daily for 12 weeks)
Trial: 22939402
Drug: Nexplanon (etonogestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nexplanon (etonogestrel implant)
Trial: 22939663
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of seven-valent pneumococcal conjugate vaccine (PCV) given at a 4-week interval
Trial: 22939663
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of seven-valent pneumococcal conjugate vaccine (PCV)